Spectrum's Fusilev patent granted extension until 2022 Spectrum announced that the U.S: Patent and Trademark Office has extended by more than two years the patent which covers Fuilev (levoleucovorin) for injection. The extension was granted through the Hatch-Waxman Act and extends the original December 31, 2019 expiration date to March 7, 2022.
News For SPPI From The Last 14 Days
Check below for free stories on SPPI the last two weeks.
Spectrum reports Q1 EPS (5c), consensus (16c) Reports Q1 revenue $38.7M, consensus $36.42M. Says pivotal data in relapsed/refractory peripheral T-cell lymphoma from late-stage drug Belinostat to be presented as an oral presentation at ASCO 2013; the company expects to submit an NDA this summer. Company expects enrollment in the Captisol-enabled melphalan study in multiple myeloma to be completed in 2013, with NDA submission in 2014.